Q-omics provides the consensus-scored MIR583HG profile across patient tissues and cancer cell-line models. MIR583HG expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIR583HG is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, MIR583HG RNA expression shows 10,257 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, LIHC, and TGCT as cancer lineages where MIR583HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR583HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR583HG survival associations across molecular data types. MIR583HG RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR583HG RNA expression–survival associations across cancer types. High MIR583HG expression shows unfavorable associations in KIRC, HNSC, STAD and LIHC, but favorable associations in SKCM and PAAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for MIR583HG RNA expression.
This table summarizes MIR583HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR583HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR583HG shows lower tumor expression in BRCA, THCA, STAD and KICH and higher tumor expression in LIHC and KIRC. The LIHC box plot shows higher MIR583HG RNA expression in tumor versus normal tissue (log2 FC = +0.317, t-test p < 0.001).
This table shows molecular features associated with MIR583HG in patient tissues and cancer cell lines. In patient samples, MIR583HG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
